Showing 1 - 10 of 35
Persistent link: https://www.econbiz.de/10010345596
Persistent link: https://www.econbiz.de/10010416365
Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in...
Persistent link: https://www.econbiz.de/10013312516
Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in...
Persistent link: https://www.econbiz.de/10012458199
to make U.S. pharmaceuticals. The current financial crisis, and the limited resources and tighter budgets it has … engendered, may accelerate the trend. Yet, China is dogged by a history of poor-quality pharmaceuticals that have killed hundreds …
Persistent link: https://www.econbiz.de/10014152593
Persistent link: https://www.econbiz.de/10009509405
Persistent link: https://www.econbiz.de/10009548834
Persistent link: https://www.econbiz.de/10009530131
"Substandard and counterfeit drugs represent a global public health crisis. However, there is little economic analysis of the market given the paucity of data. Focusing on 8 drug types on the WHO-approved medicine list, we constructed an original dataset of 899 drug samples from 17 low- and...
Persistent link: https://www.econbiz.de/10008933532
Persistent link: https://www.econbiz.de/10011408590